Crescent BioPharma: H.C. Wainwright raises to buy from neutral
CBIO•H.C. Wainwright raised its rating on Crescent BioPharma to buy from neutral.
Related News
LPL Financial Holdings Inc.: BMO cuts target price to $370 from $390
LPLA•
Personalis, Inc.: BTIG cuts to neutral from buy
PSNL•
O-I Glass Inc: BofA Global Research cuts price objective to $7.00 from $9.00
OI•
Beeline forecasts Q3 2026 revenue highest since 2021, cash up at least 50% from Q2
BLNE•
Extreme Networks schedules fiscal Q1 2027 results conference call
EXTR•